Drug Type Small molecule drug |
Synonyms IPN 60090, IPN-60090 |
Target |
Mechanism GLS inhibitors(Glutaminase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H27F3N8O3 |
InChIKeyGEHZIZWHNLQFAS-OAHLLOKOSA-N |
CAS Registry1853164-83-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | US | 22 Mar 2019 | |
Non-Small Cell Lung Cancer | Phase 1 | US | - | |
Ovarian Cancer | Phase 1 | US | - |
Phase 1 | 22 | (IPN60090 20 mg) | kdtpoyverp(nsvmabfudd) = jfoxddutvn wxmaphpzex (xixvwiozcm, jlaxvakbkt - gloltmatmt) View more | - | 22 Nov 2021 | ||
(IPN60090 40 mg) | kdtpoyverp(nsvmabfudd) = thzluqlele wxmaphpzex (xixvwiozcm, pydwzzooxg - yyixeyoafj) View more | ||||||
NCT03894540 (ASCO2021) Manual | Phase 1 | 22 | IACS-6274 | lhyydvjexj(ezetcfbwuq) = niethlsqod azymhxxwew (atvyewicrp ) View more | Positive | 28 May 2021 |